{
    "$schema": "https://github.com/Open-Systems-Pharmacology/QualificationPlan/releases/download/v1.0/OSP_Qualification_Plan_Schema.json",
    "Projects": [
        {
            "Id": "Raltegravir",
            "Path": "https://raw.githubusercontent.com/Incei/Raltegravir-Model/master/Raltegravir.json",
            "BuildingBlocks": []
        }
    ],
    "Intro": [
        {
            "Path": "Content/titlepage.md"
        }
    ],
    "Plots": {
        "PlotSettings": {
            "ChartWidth": 500,
            "ChartHeight": 400,
            "Fonts": {
                "AxisSize": 11,
                "LegendSize": 9,
                "OriginSize": 9,
                "FontFamilyName": "Arial",
                "WatermarkSize": 40
            }
        },
        "AxesSettings": {
            "ComparisonTimeProfile": [
                {
                    "Unit": "h",
                    "Dimension": "Time",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Unit": "µg/l",
                    "Dimension": "Concentration (mass)",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "DDIRatioPlotsPredictedVsObserved": [
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "DDIRatioPlotsResidualsVsObserved": [
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Linear"
                }
            ],
            "GOFMergedPlotsPredictedVsObserved": [
                {
                    "Unit": "µg/l",
                    "Dimension": "Concentration (mass)",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Unit": "µg/l",
                    "Dimension": "Concentration (mass)",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "GOFMergedPlotsResidualsOverTime": [
                {
                    "Unit": "h",
                    "Dimension": "Time",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Linear"
                }
            ],
            "PKRatioPlots": [
                {
                    "Unit": "year(s)",
                    "Dimension": "Age",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ]
        },
        "GOFMergedPlots": [
            {
                "Title": "Goodness-of-fit visual diagnostic plots of the raltegravir PBPK model performance: observed versus individually predicted plasma concentration versus time of all adult data.",
                "SectionId": 41,
                "PlotType": "predictedVsObserved",
                "Groups": [
                    {
                        "Caption": "Raltegravir lactose formulation",
                        "Symbol": "Triangle",
                        "OutputMappings": [
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 10 mg   (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 25 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 50 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 100 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 200 mg   (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 800 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 1200 mg   (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 1600 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "Raltegravir filmcoated tablet",
                        "Symbol": "Circle",
                        "OutputMappings": [
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 100 mg filmcoated tablet md",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Markowitz_2006_100 mg bid 10 days",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 200 mg filmcoated tablet md",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Markowitz_2006_200 mg bid 10 days",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 200 mg filmcoated tablet md",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400 mg filmcoated tablet md",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Markowitz_2006_400 mg bid 10 days",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg filmcoated tablet",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Rhee 2014 400mg film-coated tablet (fasted) logscale",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "Raltegravir chewable tablet",
                        "Symbol": "Asterisk",
                        "OutputMappings": [
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg chewable fasted",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Rhee 2014 4x100mg chewable tablet (fasted) logscale",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg chewable fed",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Rhee 2014 4x100mg chewable tablet (fed) logscale",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "Raltegravir granules in suspension",
                        "Symbol": "Square",
                        "OutputMappings": [
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg (granules in suspension) lsf",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Rhee 2014 400mg granules in suspension (fasted) logscale",
                                "Color": "#000000"
                            }
                        ]
                    }
                ]
            },
            {
                "Title": "Goodness-of-fit visual diagnostic plots of the raltegravir PBPK model performance: weighted residuals versus time of all adult data.",
                "SectionId": 41,
                "PlotType": "residualsOverTime",
                "Groups": [
                    {
                        "Caption": "Raltegravir lactose formulation",
                        "Symbol": "Triangle",
                        "OutputMappings": [
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 10 mg   (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 25 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 50 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 100 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 200 mg   (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 800 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 1200 mg   (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 1600 mg  (lactose formulation)",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "Raltegravir filmcoated tablet",
                        "Symbol": "Circle",
                        "OutputMappings": [
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 100 mg filmcoated tablet md",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Markowitz_2006_100 mg bid 10 days",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 200 mg filmcoated tablet md",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Markowitz_2006_200 mg bid 10 days",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 200 mg filmcoated tablet md",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400 mg filmcoated tablet md",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Markowitz_2006_400 mg bid 10 days",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg filmcoated tablet",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Rhee 2014 400mg film-coated tablet (fasted) logscale",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "Raltegravir chewable tablet",
                        "Symbol": "Asterisk",
                        "OutputMappings": [
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg chewable fasted",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Rhee 2014 4x100mg chewable tablet (fasted) logscale",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg chewable fed",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Rhee 2014 4x100mg chewable tablet (fed) logscale",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "Raltegravir granules in suspension",
                        "Symbol": "Square",
                        "OutputMappings": [
                            {
                                "Project": "Raltegravir",
                                "Simulation": "Raltegravir 400mg (granules in suspension) lsf",
                                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Rhee 2014 400mg granules in suspension (fasted) logscale",
                                "Color": "#000000"
                            }
                        ]
                    }
                ]
            }
        ],
        "AllPlots": [
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg chewable fasted",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg chewable fed",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 100 mg filmcoated tablet md",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 200 mg filmcoated tablet md",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400 mg filmcoated tablet md",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg filmcoated tablet",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg (granules in suspension) lsf",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 10 mg   (lactose formulation)",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 100 mg  (lactose formulation)",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 1200 mg   (lactose formulation)",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 1600 mg  (lactose formulation)",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 200 mg   (lactose formulation)",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 25 mg  (lactose formulation)",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg (lactose formulation)",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 50 mg  (lactose formulation)",
                "SectionId": 42
            },
            {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 800 mg  (lactose formulation)",
                "SectionId": 42
            }
        ]
    },
    "Inputs": [
        {
            "Project": "Raltegravir",
            "Name": "Raltegravir",
            "Type": "Compound",
            "SectionId": 40
        }
    ],
    "Sections": [
        {
            "Id": 1,
            "Title": "1 Introduction",
            "Content": "Content/Section1_Introduction.md"
        },
        {
            "Id": 2,
            "Title": "2 Methods",
            "Content": "Content/Section2_Methods.md",
            "Sections": [
                {
                    "Id": 21,
                    "Content": "Content/Section2.1_Modeling_Strategy.md",
                    "Title": "2.1 Modeling strategy"
                },
                {
                    "Id": 22,
                    "Content": "Content/Section2.2_Data_used.md",
                    "Title": "2.2 Data used"
                },
                {
                    "Id": 23,
                    "Content": "Content/Section2.3_Model_Parameters_and_Assumptions.md",
                    "Title": "2.3 Model parameters and assumptions"
                }
            ]
        },
        {
            "Id": 2,
            "Content": "Content/Section3_Results_and_Discussion.md",
            "Title": "3 Results and Discussion",
            "Sections": [
                {
                    "Id": 40,
                    "Content": "Content/Input_table.md",
                    "Title": "3.1   Raltegravir final PK parameter tables"
                },
                {
                    "Id": 41,
                    "Content": "Content/GOF_diagnostics.md",
                    "Title": "3.2 Raltegravir Diagnostics Plots"
                },
                {
                    "Id": 42,
                    "Content": "Content/Concentration_time_profiles.md",
                    "Title": "3.3: Raltegravir Concentration-Time profiles"
                }
            ]
        },
        {
            "Id": 3,
            "Content": "Content/Section4_Conclusion.md",
            "Title": "4 Conclusion"
        },
        {
            "Id": 4,
            "Content": "Content/References.md",
            "Title": "References"
        }
    ]
}